Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Avacincaptad pegol (IZERVAY) resulted in a change in best-corrected visual acuity (BCVA) of +1.39 letters (95% CI -5.89 to 8.67) at 2 mg and -0.28 letters (95% CI -8.74 to 8.18) at 4 mg, indicating no clinically meaningful change in BCVA. The drug probably reduced geographic atrophy (GA) lesion growth by 30.5% at 2 mg and 25.6% at 4 mg.
• Comparatively, pegcetacoplan showed similar reductions in GA lesion growth but no meaningful change in BCVA, while lampalizumab had no significant impact on either outcome. Both avacincaptad pegol and pegcetacoplan were more effective in reducing GA lesion growth than lampalizumab.
• Avacincaptad pegol (IZERVAY) may have increased the risk of macular neovascularization (MNV) with a relative risk of 3.13 (95% CI 0.93 to 10.55), though no cases of endophthalmitis were reported in the study.
• Comparatively, pegcetacoplan demonstrated a higher risk of MNV (RR 4.47 for monthly dosing, 95% CI 0.41 to 48.98), with an endophthalmitis incidence of 6 per 1000 for monthly dosing. Lampalizumab showed a lower risk of MNV (RR 1.77 for monthly dosing, 95% CI 0.73 to 4.30) and an endophthalmitis incidence of 4 per 1000.
• The study on avacincaptad pegol (IZERVAY) focused on participants with extrafoveal or juxtafoveal geographic atrophy (GA), while comparisons with other drugs showed that pegcetacoplan demonstrated possibly greater benefits in reducing GA lesion growth, particularly in participants with extrafoveal GA, with reductions of 26.1% for monthly dosing and 23.3% for every-other-month dosing.